The role of progestogens in regulating matrix metalloproteinase activity in macrophages and microglial cells

Neurochemical Research

Volumn 36, Issue 10, 2011, Pages 1870-1875

  Hwang Levine, Juliana ^a,b   Stanczyk, Frank Z ^b   Hodis, Howard N ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Estradiol; Hormone therapy; Matrix metalloproteinase; Menopause; Progesteron

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; DEOXYCORTICOSTERONE; DRUG METABOLITE; ESTRADIOL; GELATINASE B; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PREGNANEDIOL; PROGESTERONE;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INJURY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME REGULATION; HORMONE ACTION; HORMONE RESPONSE; MACROPHAGE; MICROGLIA; MOUSE; NERVE REGENERATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; STROKE;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD-BRAIN BARRIER; CELL LINE; ESTRADIOL; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MEDROXYPROGESTERONE ACETATE; MICROGLIA; PROGESTERONE; PROGESTINS;

EID: 80955180069     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0508-0     Document Type: Article

References (21)

1. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL (1990) Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 41:399-410 (Pubitemid 20134348)
2. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273:199-208
3. de Lignières B (2002) Effects of progestogens on the postmenopausal breast. Climacteric 5:229-235
4. Hwang J, Hodis HN, Hsiai TK, Asatryan L, Sevanian A (2006) Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: The modulating effect of statins. Atherosclerosis 189:76-82 (Pubitemid 44441275)
5. Mueck AO, Seeger H, Wallwiener D (2002) Medroxyprogesterone acetate versus norethisterone: Effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 9:273-281 (Pubitemid 34743452)
6. Potier M, Karl M, Elliot SJ, Striker GE, Striker LJ (2003) Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice. Am J Physiol Endocrinol Metab 285:E1237-E1245 (Pubitemid 37464374)
7. Busti C, Falcinelli E, Momi S, Gresele P (2010) Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med 5:13-25
8. Adibhatla RM, Hatcher JF (2008) Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: Therapeutic strategies. CNS Neurol Disord Drug Targets 7:234-253
9. Lincoln DW, Phillips PG, Bove K (2003) Estrogen-induced Ets-1 promotes capillary formation in an in vitro tumor angiogenesis model. Breast Cancer Res Treat 78:167-178 (Pubitemid 36433910)
10. Wingrove CS, Garr E, Godsland IF, Stevenson JC (1998) 17betaoestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1406:169-174 (Pubitemid 28193070)
11. Lee YJ, Lee EB, Kwon YE, Lee JJ, Cho WS, Kim HA, Song YW (2003) Effect of estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue inhibitor of metalloproteinase-1 in osteoarthritis chondrocytes. Rheumatol Int 23:282-288 (Pubitemid 37518611)
12. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER (2003) Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 23:1633-1646 (Pubitemid 36246045)
13. Zhang J, Salamonsen LA (2002) In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J Clin Endocrinol Metab 87:2346-2351 (Pubitemid 34521529)
14. Kanca H, Walter I, Miller I, Schäfer-Somi S, Izgur H, Aslan S (2011) Expression and activity of matrix metalloproteinases in the uterus of bitches after spontaneous and induced abortion. Reprod Domest Anim 46:197-204
15. Singh M (2006) Progesterone-induced neuroprotection. Endocrine 29:271-274 (Pubitemid 44097368)
16. Cai W, Zhu Y, Furuya K, Li Z, Sokabe M, Chen L (2008) Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology 55:128-138
17. Nilsen J, Brinton RD (2002) Impact of progestins on estrogeninduced neuroprotection: Synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 143:205-212 (Pubitemid 34056421)
18. Wang JM, Johnston PB, Ball BG, Brinton RD (2006) The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 25:4706-4718 (Pubitemid 40664119)
19. Lorenzi S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 43:191-196 (Pubitemid 36422625)
20. Bruno MA, Mufson EJ, Wuu J, Cuello AC (2009) Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 68:1309-1318
21. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ (2008) Amyloid- degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 5:212-224 (Pubitemid 351536346)